A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525673-39-00

Enrollment

Registered

2026-08-25

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis (AD)

Brief summary

Percentage change from baseline in EASI at Week 24

Detailed description

Note: All are assessed at Week 24. 1. Proportion of participants achieving at least 75% improvement from baseline in EASI (EASI-75) 2. Proportion of participants with vIGA-AD 0/1 and a decrease in vIGAAD of ≥ 2 points from baseline 3. Proportion of participants with an improvement of ≥ 4 points from baseline in peak pruritus NRS (PP-NRS) weekly average of the daily scores

Interventions

DRUGCamoteskimab

DRUGIsotonische Natriumchlorid-Lösung 0

DRUG9 %EIFELFANGO®

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage change from baseline in EASI at Week 24	—

Secondary

Measure	Time frame
Note: All are assessed at Week 24. 1. Proportion of participants achieving at least 75% improvement from baseline in EASI (EASI-75) 2. Proportion of participants with vIGA-AD 0/1 and a decrease in vIGAAD of ≥ 2 points from baseline 3. Proportion of participants with an improvement of ≥ 4 points from baseline in peak pruritus NRS (PP-NRS) weekly average of the daily scores	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 26, 2026